| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/24/2005 | WO2005016270A2 Methods for treatment of dermatological conditions |
| 02/24/2005 | WO2005016269A2 Methods for treating metabolic syndrome |
| 02/24/2005 | WO2005016265A2 Method for promoting bone growth |
| 02/24/2005 | WO2005016264A2 Diamine derivatives of quinone and uses thereof |
| 02/24/2005 | WO2005016262A2 Methods for administering aripiprazole |
| 02/24/2005 | WO2005016261A2 Aripiprazole and haloperidol pamoate salts |
| 02/24/2005 | WO2005016255A2 Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds |
| 02/24/2005 | WO2005016254A2 Methods and reagents for treating inflammation and fibrosis |
| 02/24/2005 | WO2005016252A2 Phosphorus-containing macrocycles |
| 02/24/2005 | WO2005016249A2 Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ace inhibitor for the treatment of central nervous system damage |
| 02/24/2005 | WO2005016245A2 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof |
| 02/24/2005 | WO2005016243A2 Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders |
| 02/24/2005 | WO2005016242A2 Synthetic process for trans-aminocyclohexyl ether compounds |
| 02/24/2005 | WO2005016239A2 Molecules enhancing dermal delivery of influenza vaccines |
| 02/24/2005 | WO2005016235A2 Combined use of impdh inhibitors with toll-like receptor agonists |
| 02/24/2005 | WO2005016234A2 Compositions, methods, apparatuses, and systems for singlet oxygen delivery |
| 02/24/2005 | WO2005016231A2 Agents and methods for treatment of disease by oligosaccharide targeting agents |
| 02/24/2005 | WO2005016229A2 Use of lipophilic diesters of chelating agent for the treatment of amyloidosis and atherosclerosis |
| 02/24/2005 | WO2005016228A2 Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders |
| 02/24/2005 | WO2005016227A2 Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof |
| 02/24/2005 | WO2005016225A2 Stable pharmaceutical composition of rabeprazole |
| 02/24/2005 | WO2005016196A1 Compositions and methods for destabilizing lysosomes to increase oncogenic or aberrant protein degradation |
| 02/24/2005 | WO2005016031A1 Methods for reducing astringency |
| 02/24/2005 | WO2005009338A3 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/24/2005 | WO2005007084A3 Pancratistatin cyclic phosphate prodrugs an phenpanstatin cyclic phosphate prodrugs |
| 02/24/2005 | WO2005005431A3 7-polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups |
| 02/24/2005 | WO2005005393A3 Cck-1 receptor modulators |
| 02/24/2005 | WO2005004880A8 Vaginal compositions for treating pelvic tissue infections and traumas |
| 02/24/2005 | WO2005000312A8 Sustained drug-relase particles and process for producing the same |
| 02/24/2005 | WO2004110492A3 Composition comprising triptans and nsaids |
| 02/24/2005 | WO2004110376A3 Ccr-2 antagonists for treatment of neuropathic pain |
| 02/24/2005 | WO2004108745A3 11-12 bicyclic erythromycin derivatives |
| 02/24/2005 | WO2004100876A3 The aerosolization of cromolyn sodium using a capillary aerosol generator |
| 02/24/2005 | WO2004096862B1 Improved extration and purification method for cereal beta (1-3) beta (1-4) glucan |
| 02/24/2005 | WO2004096235A8 Anti-cancer phosphonate analogs |
| 02/24/2005 | WO2004093907A3 Therapeutic agents for treating dermatitis, alopecia and itching and transgenic animals for evaluating such therapeutic agents |
| 02/24/2005 | WO2004093799A3 Thyroid receptor ligands |
| 02/24/2005 | WO2004093789A3 Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| 02/24/2005 | WO2004091529A3 Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom |
| 02/24/2005 | WO2004091436A3 Methods and compositions for treating ocular disease |
| 02/24/2005 | WO2004089970A3 Crystalline 19-norsteroids |
| 02/24/2005 | WO2004087066A3 Hif-1 inhibitors |
| 02/24/2005 | WO2004087056A3 BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ |
| 02/24/2005 | WO2004084818A3 Measurement of estrogen activity in plants and a composition therefrom |
| 02/24/2005 | WO2004082668A8 Coenzyme q10-containing proliposome and preparation thereof |
| 02/24/2005 | WO2004082622A3 Retinoid replacements and opsin agonists and methods for the use thereof |
| 02/24/2005 | WO2004082593A3 Pharmaceutical compositions of cetp inhibitors |
| 02/24/2005 | WO2004080450A3 Combined use of a fibrate and orlistat for the treatment of obesity |
| 02/24/2005 | WO2004077062B1 Method for selecting a candidate drug compound |
| 02/24/2005 | WO2004071424A3 Immediate release formulation of n-(2-propylpentanoyl)glycinamide |
| 02/24/2005 | WO2004071403A3 Coated particles and pharmaceutical dosage forms |
| 02/24/2005 | WO2004070000A3 Htlv-i-cell binding and inhibition |
| 02/24/2005 | WO2004069258A3 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma |
| 02/24/2005 | WO2004069181A3 Composition for the treatment of intraocular pressure |
| 02/24/2005 | WO2004066990B1 Methods of treating lower urinary tract disorders using sodium channel modulators |
| 02/24/2005 | WO2004066987B1 Use of sodium channel modulators for treating gastrointestinal tract disorders |
| 02/24/2005 | WO2004060287A3 Use of 2-nitropropanol, 2-nitroethane, and 2-nitroethanol for control of microbial pathogens |
| 02/24/2005 | WO2004058235A3 Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative |
| 02/24/2005 | WO2004052299A8 Modification of cyclooxygenase and lipoxygenase activity with asteridae extracts and optionally boswellic acid |
| 02/24/2005 | WO2004052293A3 Recombinant vaccine against flavivirus infection |
| 02/24/2005 | WO2004047831A3 Use of a pparalpha agonist and metformin for decreasing the serum triglycerides |
| 02/24/2005 | WO2004046103A3 Arylpyridine compounds |
| 02/24/2005 | WO2004037163A3 STERICALLY-AWKWARD β-LACTAMASE INHIBITORS |
| 02/24/2005 | WO2004015062A3 Methods and compositions relating to gene silencing |
| 02/24/2005 | WO2004014305A3 Method and compositions for inducing production of fibrous organic tissue |
| 02/24/2005 | WO2004012677A3 Methods and compositions to treat conditions associated with neovascularization |
| 02/24/2005 | WO2004010997A8 Sustained-release tablet composition of pramipexole |
| 02/24/2005 | WO2004009064A8 Use of neurotoxic substances for the production of a means for the treatment of joint pain and method for application of said means |
| 02/24/2005 | WO2004002472A8 Carvedilol hydrobromide |
| 02/24/2005 | WO2003102206A3 Sgk and nedd used as diagnostic and therapeutic targets |
| 02/24/2005 | WO2003099851A3 Methods and compositions for inhibiting hiv replication |
| 02/24/2005 | WO2003093503A3 Method for bioequivalence determination using expression profiling |
| 02/24/2005 | WO2003090721A3 Method for producing crystals from active ingredients in medicaments, and the use thereof in pharmaceutical formulations |
| 02/24/2005 | WO2003061362A3 Methods and compositions for treating polycystic ovary syndrome |
| 02/24/2005 | WO2003002062A3 Bis-aryl thiazole derivatives |
| 02/24/2005 | US20050043788 Drug-eluting stent |
| 02/24/2005 | US20050043773 Methods of improving the safety of zonisamide therapy |
| 02/24/2005 | US20050043705 Methods of using zonisamide as an adjunctive therapy for partial seizures |
| 02/24/2005 | US20050043704 Methods of using zonisamide as an adjunctive therapy for partial seizures |
| 02/24/2005 | US20050043551 Reacting furfural and nitromethane, with isobuthylamine as catalyst and activated coal as adsorbent; centrifugation; vacuum filtration; crystallization |
| 02/24/2005 | US20050043549 Novel diterpene compounds |
| 02/24/2005 | US20050043545 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors |
| 02/24/2005 | US20050043544 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| 02/24/2005 | US20050043540 such as cis-4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]-N-methyl-N-(3-phenyl-2(E)-propenyl)-benzenemethanamine; |
| 02/24/2005 | US20050043536 Sulfonamides |
| 02/24/2005 | US20050043535 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists |
| 02/24/2005 | US20050043523 Benzothiazole derivative compounds, compositions and uses |
| 02/24/2005 | US20050043511 G-protein coupled receptor lustr2 and uses thereof |
| 02/24/2005 | US20050043481 Material consisting of at least a biodegradable polymer and cyclodextrins |
| 02/24/2005 | US20050043413 Active ingredient for producing a substance containing isocitrate for influencing the coagulation tendency of blood |
| 02/24/2005 | US20050043412 Remedies for glaucoma comprising bunazosin and prostaglandins |
| 02/24/2005 | US20050043410 Using an epinephrine type compound; controlling neovascularization |
| 02/24/2005 | US20050043409 Combinations comprising a selective cyclooxygenase-2 inhibitor |
| 02/24/2005 | US20050043408 Prevent protein glycation; drug screening; using epinephrine compound |
| 02/24/2005 | US20050043407 Opioid receptor antagonist and cannabinoid receptor antagonist for treatment of alcohol, cocaine, and/or tobacco dependence |
| 02/24/2005 | US20050043406 Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| 02/24/2005 | US20050043405 Omega-3 fatty acids for osteoarthritis |
| 02/24/2005 | US20050043402 Methods and formulations for counteracting infection of mucosa or skin |
| 02/24/2005 | US20050043400 Mixture of zinc acetate and zinc gluconate; sustained release; bioavailability |
| 02/24/2005 | US20050043399 Dimeric compounds and their use as anti-viral agents |